Chemomab Therapeutics (CMMB) Profit After Tax (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Profit After Tax data on file, last reported at $1.9 million in Q4 2025.

• Quarterly Profit After Tax fell 36.79% year-over-year to $1.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.8 million (down 67.62% YoY) and the FY2025 annual result came in at -$9.0 million, up 35.5% from the prior year.
• Profit After Tax improved to $1.9 million in Q4 2025, from $1.7 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $8.1 million in Q3 2022 to a low of -$47.0 million in Q4 2022.
• A 5-year average of -$4.7 million and a median of -$2.4 million in 2021 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 372.24% in 2022, down 833.68% in 2022.
• Tracing CMMB's Profit After Tax over 5 years: stood at -$5.0 million in 2021, then slumped by 833.68% to -$47.0 million in 2022, then grew by 4.24% to -$45.0 million in 2023, then jumped by 106.58% to $3.0 million in 2024, then plunged by 36.79% to $1.9 million in 2025.
• The last three Profit After Tax figures came in at $1.9 million (Q4 2025), $1.7 million (Q3 2025), and -$2.1 million (Q2 2025), per Business Quant data.